Kidney/Renal Disease

Show Only Open Trials
2.

Using mTOR Inhibitors in the Prevention of BK Nephropathy

  • Study Status: Open to Enrollment
  • Sponsor: Pfizer, Columbia University
3.

BMS CA204007: A Phase 1b Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: Multiple Multiple and Normal Renal Function, Severe Renal Impairment, or on Dialysis
  • Protocol ID: BMS CA204007
4.

Characterization of Intestinal Microbiota to Evaluate Kidney Allograft Status

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Clinical and Translational Science Center
5.

RESTARRT: Immunosuppression with Anti-thymocyte Globuline, Rituximab, Tacrolimus, and Sirolimus, Followed by Withdrawal of Tacrolimus and Sirolimus, in Living-donor Renal Transplant Recipients

  • Study Status: Open to Enrollment
  • Sponsor: NIAID; Immune Tolerance Network (ITN)
  • Disease Status and/or Stage: Renal Transplant Recipients
6.

Use of PCR to Evaluate Renal Allograft Status (Diagnostic and Serial Biopsies)

  • Study Status: Open to Enrollment
  • Sponsor: NIH; Qatar National Research Foundation (QNRF); Quest Diagnostics, Inc.
7.

Evaluation of Subclinical Renal Allograft Damage

  • Study Status: Open to Enrollment
  • Sponsor: NIAID/NIH; Qatar National Research Foundation (QNRF)
8.

Top of page